-
Precision Pruning with PROTACs: Selective Targeting of Toxic Huntingtin
Latest News
-
CHDI Report: Day 3
Day 3 of CHDI’s HD therapeutics conference: growth factors and CHDI’s advanced therapies
-
CHDI Report: Day 2
Day 2 of CHDI’s HD therapeutics conference: figuring out energy problems in HD
-
CHDI Report: Day 1
Day 1 of CHDI’s HD therapeutics conference: exploring abnormal brain connections and silencing the HD gene
-
Anti-nausea drug helps cells with the HD mutation stay healthy in a surprising way
Anti-nausea drug meclizine protects cells with the HD mutation from death by reducing cellular energy production
-
HDBuzz takes your questions to the annual therapeutics meeting of CHDI
HDBuzz visits Palm Springs to talk with CHDI about the latest HD research. Send us your questions!
-
Welcome to HDBuzz
Welcome to HDBuzz. Huntington’s disease research news. In plain language. Written by scientists. For the global HD co
-
Memantine in HD: dose is everything
Memantine, a drug already used in Alzheimer’s disease, might help in HD, but a mouse study shows dose is everything.
-
An active lifestyle may make a difference to HD symptoms
More reasons to be active: a passive lifestyle may contribute to earlier onset of symptoms in HD.
-
Frequently asked questions, January 2011
Answers to frequently-asked questions about HD – the first in a regular series of HDBuzz FAQ articles.
-
Getting the data out – a new scientific journal just for HD
New scientific journal PLoS Currents HD promises rapid publication & open access, improving scientific communication
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
